EN DE
Watch Zevra Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zevra Therapeutics Inc. (ZVRA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Zevra Therapeutics Inc. stock $13.04, price $11.59, upside +12.5%, quality 53 out of 100. Rating: undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

ZT Zevra Therapeutics Inc. logo Some data Nov 6, 2026

Zevra Therapeutics Inc.

ZVRA · US
Undervalued, in an uptrend

The stock costs 11% less than our calculation considers fair.

Fair value $13.04 · Undervalued
Highly profitable · 52.8% net margin (TTM)
Low debt
Generates free cash flow over the last twelve months
Ranks above peers (10/13)
Wide moat 89/100
Revenue last quarter +45% vs. a year ago.
Quality 53/100
Mixed Growth (revenue 5y +51.6 %/yr in USD)
Insiders sold $1.3M (6M)
Some data
Watch Zevra Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.75 $4.02 Fair Value $13.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $4.02 – $14.75 · fair‑value band $7.59 – $35.62 · the $11.59 price screens below the $13.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Zevra Therapeutics in your weekly email

Every Wednesday you see whether Zevra Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.

Show moreShow less

Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.

The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease.

The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Stock analysis

Zevra Therapeutics Inc. (ZVRA) currently trades at $11.59, while our model-based Fair Value estimate is $13.04, implying the stock looks roughly 11% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $64.98 per share, and 7 of the 10 models we run sit above the $11.59 price.

Bear case: the Asset-Based group reads lowest at $1.56, and 3 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $7.59 (bear) to $35.62 (bull), the price of $11.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Zevra Therapeutics Inc. reported revenue of $106M in FY2025 versus $28.7M in FY2021, a compound +38.8%/yr. Reported net income was $83.2M in FY2025.

Key figures

Market cap $711M Small · P/E ratio 9.5 · P/S ratio 4.81 · EPS (TTM) $1.22 · Net margin 52.8% · Return on equity 41.9% · Return on assets (EBIT) −22.0% (5-year average) · Operating margin 30.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 89 out of 100 (medium confidence).

What moves the price

The share trades about 21% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 13%, ZVRA screens cheaper than that median.

Fair Value models

Bear $7.59 Fair Value $13.04 Bull $35.62
Price $11.59 · Upside +12.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.05 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $13.92 $28.62 $55.64 70
Growth-Adj P/E $45.49 $64.98 $84.48 65
P/E Multiple $23.08 $30.77 $38.46 63
All 10 models by family
DCF Models
Owner Earnings $13.92 $28.62 $55.64 70
Earnings-Based
Graham-Dodd $9.51 $66.33 $93.08 61
Lynch FV $34.27 $48.95 $63.64 59
PEG = 1.0 $34.27 $48.95 $63.64 55
Multiples
P/E Multiple $23.08 $30.77 $38.46 63
P/S Multiple $4.70 $6.26 $7.83 58
P/B Multiple $6.47 $8.62 $10.78 55
Asset-Based
NCAV (Graham) $1.03 $1.56 $1.95 54
Economic Profit
Residual Income $7.59 $13.04 $35.62 58
Growth Earnings
Growth-Adj P/E $45.49 $64.98 $84.48 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 75
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 51
Distance to the 52-week high, does not count
New shares 5
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.3M and none bought.

  • SaleNeil F. McFarlanePresident and CEO, Director3× since Feb 2, 2026: 125,625 shares, avg. $9.58$1.2MOct 12, 202610b5-1 plan
  • SaleRahsaan ThompsonChief Legal & Compliance4× since Jan 30, 2026: 83,097 shares, avg. $11.67$969,354Aug 14, 202610b5-1 plan
  • SaleCorey Michael WattonDirector12,300 shares at $11.25$138,375Aug 10, 2026
  • SaleTimothy J. SangiovanniSVP, Finance & Corp Controller2× since Jan 30, 2026: 4,750 shares, avg. $9.05$42,975Feb 3, 202610b5-1 plan
  • SaleJoshua SchaferCCO2× since Jan 30, 2026: 13,875 shares, avg. $9.10$126,296Feb 3, 202610b5-1 plan
  • SaleAdrian W QuartelChief Medical Officer4,533 shares at $8.83$40,026Jan 30, 202610b5-1 plan

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+350.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−42.2% (2020) → −4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch ZVRA, get fair value alerts →

Compare Zevra Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside +12.5% · Top 25%
Profitability
Return on equity (12 months) 41.9% · Top 25%
Return on assets 29.2% · Top 25%
Net margin (12 months) 52.8% · Top 25%
Operating margin (12 months) 30.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 44.9% · Top 25%
Balance sheet
Debt / equity 0.40× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 9.5× · Cheapest 25%
P/B 4.60× · Priciest 25%
P/S (12 months) 4.81× · Cheaper than median
EV/EBITDA 14.8× · Cheaper than median
PEG 10.67× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)80 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ZVRA
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ZVRA
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs ZVRA
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ZVRA
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ZVRA
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs ZVRA
argenx SE ARGX $927.21 $908.40 −2% vs ZVRA
CSL Limited CSL A$202.04 A$183.04 −9% vs ZVRA
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ZVRA
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ZVRA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zevra Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zevra Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ZVRA

Frequently asked questions

Is Zevra Therapeutics Inc. (ZVRA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $13.04 versus a price of $11.59, about +13% upside (undervalued).
What is the fair value of ZVRA?
Our model-based fair value for Zevra Therapeutics Inc. is $13.04 (as of Nov 6, 2026), built from audited fundamentals. The current price: $11.59.
What is the quality score of ZVRA?
Zevra Therapeutics Inc. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zevra Therapeutics Inc. (ZVRA)?
Our model-based price target is the fair value of $13.04 (as of Nov 6, 2026) from 10 valuation models. Cautious scenario $7.59, optimistic scenario $35.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Zevra Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $13.04, about +13% upside versus a price of $11.59 (undervalued). Cautious scenario $7.59, optimistic scenario $35.62. The calculation is refreshed regularly with new filings.
What is the revenue of Zevra Therapeutics Inc. (ZVRA)?
Zevra Therapeutics Inc. reported trailing-twelve-month revenue of about $148M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Zevra Therapeutics Inc. (ZVRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zevra Therapeutics Inc. it is $13.04 per share (as of Nov 6, 2026), against a price of $11.59. It is the blended result of 10 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Zevra Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ZVRA trades below its calculated fair value: price $11.59, fair value $13.04, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZVRA?
No. The price is what the market pays today ($11.59); the fair value is what the company's own numbers justify ($13.04). For Zevra Therapeutics Inc. the two are $1.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zevra Therapeutics Inc. worth?
The market values Zevra Therapeutics Inc. at about $711M (market capitalisation, as of Nov 6, 2026). Per share that is $11.59; our models calculate a fair value of $13.04 per share.
What do the bullish and bearish scenarios say about ZVRA?
Our models span a range for Zevra Therapeutics Inc.: cautious scenario $7.59, base $13.04, optimistic $35.62 per share (as of Nov 6, 2026, price $11.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZVRA?
Zevra Therapeutics Inc. trades at a price-to-earnings ratio of 9.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.04 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 8.6 (reported for FY2025: 8.0). Other multiples: PEG 10.7, P/B 4.6, P/S 4.8, EV/EBITDA 14.8.
What is the PEG ratio of ZVRA?
The PEG ratio of Zevra Therapeutics Inc. is 10.67 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Zevra Therapeutics Inc. (ZVRA)?
Balance-sheet figures for Zevra Therapeutics Inc. (as of Nov 6, 2026): return on equity 41.9%, debt of 0.40 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is ZVRA from its 52-week high?
Zevra Therapeutics Inc. trades at $11.59, about 21% below its 52-week high of $14.75 and 43% above the low of $8.10 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $13.04 is for.
Which stocks are comparable to Zevra Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zevra Therapeutics Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price $11.59, calculated fair value $13.04 (+13%), Quality Score 53/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZVRA calculated?
We run Zevra Therapeutics Inc. through 10 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $13.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Zevra Therapeutics Inc. currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zevra Therapeutics Inc. (ZVRA)?
The closing price on Nov 6, 2026 was $11.59. Our model-based fair value is $13.04, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zevra Therapeutics Inc. right now?
The model range is unusually wide ($7.59 to $35.62). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Zevra Therapeutics Inc.

How large is the market capitalisation of Zevra Therapeutics Inc. (ZVRA)?
The market capitalisation of Zevra Therapeutics Inc. is $711M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zevra Therapeutics Inc. (ZVRA)?
The price-to-sales ratio of Zevra Therapeutics Inc. is 4.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zevra Therapeutics Inc. (ZVRA)?
Earnings per share at Zevra Therapeutics Inc. are $1.22 (price ÷ EPS = P/E 9.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zevra Therapeutics Inc. (ZVRA)?
The net margin of Zevra Therapeutics Inc. is 52.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zevra Therapeutics Inc. (ZVRA)?
The return on equity (ROE) of Zevra Therapeutics Inc. is 41.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zevra Therapeutics Inc. (ZVRA)?
On an EBIT basis the return on assets of Zevra Therapeutics Inc. is −22.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zevra Therapeutics Inc. (ZVRA)?
The operating margin of Zevra Therapeutics Inc. is 30.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zevra Therapeutics Inc. (ZVRA)?
Revenue at Zevra Therapeutics Inc. is growing +44.9% versus a year earlier (3y avg +119%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zevra Therapeutics Inc. (ZVRA)?
Earnings per share at Zevra Therapeutics Inc. are growing −88.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zevra Therapeutics Inc. (ZVRA) generate?
The free cash flow of Zevra Therapeutics Inc. is −$2.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zevra Therapeutics Inc. (ZVRA) carry?
The net debt of Zevra Therapeutics Inc. is $800K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zevra Therapeutics Inc. in the live analysis

One click puts Zevra Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.